December 02, 2022
Article
With major updates in HIV, C difficile, hepatitis, yeast infections, and skin and soft tissue infections, this week's Infectious Disease Update has something for everyone.
November 23, 2022
Podcast
Dr. Teena Chopra discusses the global need to do more to prevent healthcare-associated infections like C difficile in vulnerable patient populations.
October 26, 2022
The US FDA has accepted a Biologics License Application (BLA) for Seres Therapeutics' SER-109, and set a Prescription Drug User Fee Act (PDUFA) action date of April 26, 2023.
September 29, 2022
Video
C diff patients live in fear of a recurrence, says gastroenterologist Paul Feuerstadt, MD. RBX2660 has entered the FDA pipeline and looks to end this vicious cycle.
September 27, 2022
A fecal microbiota transplant (FMT) trial was halted early due to clear evidence the treatment was superior to placebo.
September 16, 2022
Compared to fidaxomicin and vancomycinfecal, microbiota transplant (FMT) was the most cost-effective treatment for first and subsequent recurrent C difficile infection.
July 25, 2022
Frequent recurrence of Clostridioides difficile infection drives up financial burdens of the disease and underscores the need to improve access to treatment, infection prevention, and new therapies.
June 20, 2022
Eric Shaff, president and CEO of Seres Therapeutics, discusses the confirmatory trial findings for SER-109. Seres is filing a Biologics License Application for the recurrent C diff therapy.
June 08, 2022
SER-109, the investigational oral microbiome therapeutic from Seres, reduced C diff recurrence by 91.3% in at-risk populations.
May 23, 2022
Seres Therapeutics shared phase 3 trial results demonstrating their investigational microbiome-based therapeutic, SER-109, prevented recurrent C difficile infection (rCDI) in 88% of recipients.
Infectious Disease Update: This Week's Top 5 Stories
Experimental HIV Vaccine Elicits Broadly Neutralizing Antibodies
Considering Criteria for Admission for Skin and Soft Tissue Infections
Utilizing a Novel Modality to Treat Pulmonary Fungal Infections in Lung Transplant Patients
